CUE - Cue Biopharma Inc Stock Price, Fair Value and News

1.72USD-0.02 (-1.15%)Delayed

Market Summary

USD1.72-0.02

Delayed

-1.15%

CUE Stock Price

View Fullscreen

CUE RSI Chart

CUE Valuation

Market Cap

83.7M

Price/Earnings (Trailing)

-1.67

Price/Sales (Trailing)

11.92

EV/EBITDA

-1.04

Price/Free Cashflow

-2.15

CUE Price/Sales (Trailing)

CUE Profitability

EBT Margin

-755.13%

Return on Equity

-166.36%

Return on Assets

-92.62%

Free Cashflow Yield

-46.57%

CUE Fundamentals

CUE Revenue

Revenue (TTM)

7.0M

Rev. Growth (Yr)

818.18%

Rev. Growth (Qtr)

-5.71%

CUE Earnings

Earnings (TTM)

-50.0M

Earnings Growth (Yr)

5.81%

Earnings Growth (Qtr)

8.09%

Breaking Down CUE Revenue

Last 7 days

-1.1%

Last 30 days

5.5%

Last 90 days

-21.5%

Trailing 12 Months

-56.9%

How does CUE drawdown profile look like?

CUE Financial Health

Current Ratio

2.47

Debt/Equity

0.11

Debt/Cashflow

-12

CUE Investor Care

Shares Dilution (1Y)

12.66%

Diluted EPS (TTM)

-1.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	7.0M	0	0	0
2023	432.0K	1.8M	3.8M	5.5M
2022	14.4M	11.7M	9.3M	1.2M
2021	3.8M	5.5M	7.2M	14.9M
2020	4.0M	4.0M	3.7M	3.2M
2019	1.7M	2.3M	2.9M	3.5M
2018	0	0	0	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cue Biopharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 25, 2023	suri anish	bought	11,040	2.76	4,000	president and cso
Aug 14, 2023	passeri daniel r	bought	8,580	2.86	3,000	chief executive officer
Mar 23, 2023	kiener peter a	sold	-30,586	3.28	-9,325	-
Mar 23, 2023	kiener peter a	acquired	27,690	2.86	9,682	-
Aug 22, 2022	millar kerri-ann	sold (taxes)	-8,625	3.05	-2,828	chief financial officer
Aug 21, 2022	millar kerri-ann	acquired	-	-	6,667	chief financial officer
Jun 14, 2022	gray cameron	sold (taxes)	-164,998	3.2	-51,562	-
Jun 14, 2022	gray cameron	acquired	165,000	2.7	61,111	-
May 27, 2022	morich frank	bought	105,000	3.75	28,000	-
May 24, 2022	fletcher aaron g.l.	bought	183,700	3.34	55,000	-

Which funds bought or sold CUE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Tidal Investments LLC	new	-	21,947	21,947	-%
May 16, 2024	COMERICA BANK	added	37.47	-62.00	3,827	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-144,220	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.92	-8,799	6,838	-%
May 15, 2024	Robertson Stephens Wealth Management, LLC	unchanged	-	-358,875	904,365	0.05%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-21.75	-67,720	86,255	-%
May 15, 2024	Royal Bank of Canada	reduced	-91.97	-31,000	2,000	-%
May 15, 2024	Voya Investment Management LLC	reduced	-7.69	-13,033	25,400	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	reduced	-42.00	-1,331	945	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	31.36	-43,353	684,350	-%

Are Funds Buying or Selling CUE?

Are funds buying CUE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CUE

No. of Funds

Unveiling Cue Biopharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	bleichroeder lp	6.11%	2,755,028	SC 13G
Feb 07, 2024	blackrock inc.	4.98%	2,247,978	SC 13G
Jan 31, 2024	blackrock inc.	5.2%	2,338,765	SC 13G
Feb 14, 2023	slate path capital lp	5.6%	2,402,455	SC 13G
Feb 03, 2023	state street corp	0.33%	141,153	SC 13G/A
Dec 02, 2022	nantahala capital management, llc	0.3%	93,297	SC 13G/A
Nov 18, 2022	slate path capital lp	5.6%	2,402,455	SC 13G
Jul 08, 2022	blackrock inc.	2.4%	831,925	SC 13G
Feb 14, 2022	nantahala capital management, llc	8.0%	2,539,700	SC 13G/A
Feb 14, 2022	corriente advisors, llc	0.0%	0	SC 13G/A

Recent SEC filings of Cue Biopharma Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 28, 2024	10-K	Annual Report
Mar 11, 2024	SC 13G	Major Ownership Report
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading

Peers (Alternatives to Cue Biopharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Cue Biopharma Inc News

Latest updates

Cue Biopharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-5.7%	1,717,000	1,821,000	2,100,000	1,382,000	187,000	151,000	68,000	26,000	1,000,000	8,254,370	2,395,000	2,739,000	1,553,000	475,325	704,000	1,075,000	900,000	1,049,331	984,000	1,055,000	370,000
Operating Expenses	-8.1%	14,385,000	15,653,500	13,519,000	14,899,000	13,567,000	15,017,000	11,099,000	13,116,000	15,238,000	16,137,443	15,413,000	13,042,000	14,071,000	11,449,910	10,835,000	12,017,000	13,895,000	10,065,578	8,078,000	10,286,000	11,797,000
S&GA Expenses	-100.0%	-	4,609,500	3,645,000	4,249,000	4,176,000	3,703,500	3,528,000	3,782,000	5,156,000	4,646,678	4,125,000	4,280,000	4,255,000	3,446,205	3,318,000	3,898,000	3,989,000	3,100,593	2,776,000	3,419,000	3,444,000
R&D Expenses	-6.3%	10,199,000	10,887,000	9,874,000	10,650,000	9,391,000	11,332,500	7,571,000	9,592,000	10,082,000	11,490,765	11,288,000	8,762,000	9,816,000	8,003,705	7,517,000	8,119,000	9,906,000	6,964,985	5,302,000	6,867,000	8,353,000
EBITDA Margin	21.9%	-7.65	-9.79	-14.03	-29.85	-123	-42.41	-4.60	-3.66	-2.95	-2.84	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	44.2%	-241,000	-432,000	-286,000	-232,000	-370,000	-358,000	-124,000	-206,000	-25,000	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	289,000	-	-	206,000	-	-	-	-	-500	-	413,000	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-10,896,671	-10,031,000	-10,833,000	-	-8,918,457	-6,990,000	-9,109,000	-
EBT Margin	21.8%	-7.55	-9.66	-13.88	-29.65	-122	-42.58	-4.67	-3.74	-3.03	-2.92	-5.68	-7.43	-	-	-	-	-	-	-	-	-
Net Income	8.1%	-12,347,000	-13,434,000	-11,005,000	-13,185,000	-13,109,000	-14,592,000	-10,955,000	-13,208,000	-14,255,000	-8,384,175	-12,993,000	-10,279,000	-12,505,000	-11,102,921	-10,031,000	-10,833,000	-12,818,000	-8,918,457	-6,990,000	-9,522,000	-11,267,000
Net Income Margin	23.0%	-7.12	-9.24	-13.58	-28.99	-120	-42.58	-5.01	-4.18	-3.19	-2.96	-6.55	-8.03	-	-	-	-	-	-	-	-	-
Free Cashflow	10.2%	-9,839,000	-10,958,000	-7,799,000	-10,371,000	-10,833,000	-10,515,000	-6,949,000	-12,913,000	-11,600,000	-10,645,205	-6,640,000	-10,022,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-12.3%	54.00	62.00	69.00	73.00	82.00	91.00	76.00	85.00	91.00	83.00	79.00	90.00	89.00	100	107	101	61.00	72.00	45.00	42.00	45.00
Current Assets	-13.2%	45.00	51.00	58.00	61.00	69.00	77.00	62.00	69.00	76.00	68.00	70.00	80.00	77.00	88.00	94.00	88.00	51.00	61.00	33.00	30.00	32.00
Cash Equivalents	-15.4%	41.00	49.00	55.00	53.00	56.00	52.00	30.00	66.00	68.00	64.00	68.00	74.00	73.00	75.00	72.00	60.00	23.00	44.00	31.00	24.00	22.00
Net PPE	-5.2%	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00
Liabilities	-2.2%	24.00	24.00	26.00	27.00	27.00	26.00	26.00	25.00	26.00	18.00	15.00	17.00	19.00	21.00	19.00	21.00	15.00	17.00	18.00	21.00	20.00
Current Liabilities	5.9%	18.00	17.00	17.00	16.00	14.00	12.00	10.00	8.00	11.00	13.00	15.00	17.00	17.00	16.00	14.00	15.00	12.00	12.00	10.00	11.00	11.00
Long Term Debt	-22.8%	3.00	4.00	5.00	6.00	7.00	8.00	9.00	10.00	10.00	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	4.00	5.00	6.00	7.00	8.00	9.00	10.00	10.00	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-19.0%	30.00	37.00	43.00	46.00	55.00	66.00	51.00	60.00	65.00	65.00	64.00	73.00	70.00	79.00	88.00	80.00	45.00	55.00	27.00	20.00	25.00
Retained Earnings	-4.1%	-313	-301	-287	-276	-263	-250	-235	-224	-211	-197	-189	-176	-165	-153	-142	-132	-121	-108	-99.58	-92.59	-83.07
Additional Paid-In Capital	1.6%	344	338	330	323	319	316	287	285	276	263	253	249	235	232	230	212	166	163	127	113	108
Shares Outstanding	13.0%	49.00	43.00	45.00	44.00	43.00	47.00	34.00	35.00	33.00	32.00	31.00	31.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	154	-	-	-	82.00	-	-	-	363	-	-	-	695	-	-	-	160	-

Cashflow (Last 12 Months)

(In )

Cashflow (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	10.7%	-9,784,000	-10,958,000	-7,799,000	-10,371,000	-10,833,000	-10,514,000	-6,871,000	-12,848,000	-11,573,000	-10,645,166	-6,627,000	-9,770,000	-11,795,000	-6,999,034	-7,687,000	-6,864,000	-10,944,000	-6,437,910	-9,208,000	-6,676,000	-8,475,000
Share Based Compensation	-6.1%	1,946,000	2,072,000	2,073,000	2,037,000	1,998,000	2,112,000	2,064,000	2,309,000	3,011,000	2,974,084	3,252,000	2,854,000	2,436,000	2,281,782	2,500,000	2,524,000	3,175,000	1,994,482	1,439,000	1,321,000	1,768,000
Cashflow From Investing	-Infinity%	-55,000	-	5,000,000	5,000,000	15,002,000	4,999,000	-29,520,000	-62,000	-27,000	511	-11,000	-233,000	9,352,000	9,891,874	4,654,000	-140,000	-9,950,000	-15,145,177	3,984,000	5,127,000	9,481,000
Cashflow From Financing	-50.8%	2,354,000	4,782,000	4,589,000	2,101,000	388,000	27,403,000	-9,000	11,109,000	15,156,000	7,382,322	351,000	10,666,000	834,000	244,263	15,013,000	43,321,000	36,000	34,493,765	12,292,000	3,747,000	257,000
Buy Backs	-	-	-	-	-	-	-	9,000	-	191,000	183,128	482,000	-	85,000	160,051	35,000	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CUE Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue	$ 1,717	$ 187
Operating expenses:
General and administrative	4,186	4,176
Research and development	10,199	9,391
Total operating expenses	14,385	13,567
Loss from operations	(12,668)	(13,380)
Other income (expense):
Interest income	562	641
Interest expense	(241)	(370)
Total other income (expense), net	321	271
Net loss	(12,347)	(13,109)
Unrealized gain from available-for-sale securities	0	57
Comprehensive loss	$ (12,347)	$ (13,052)
Net loss per common share, basic	$ (0.25)	$ (0.29)
Net loss per common share, diluted	$ (0.25)	$ (0.29)
Weighted average common shares outstanding, basic	49,466,711	44,652,353
Weighted average common shares outstanding, diluted	49,466,711	44,652,353

CUE Balance Sheet

2024-03-31

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 41,029	$ 48,514
Accounts receivable	1,400	1,698
Prepaid expenses and other current assets	2,240	1,242
Total current assets	44,669	51,454
Property and equipment, net	754	795
Operating lease right-of-use	5,573	6,323
Deposits	2,690	2,690
Restricted cash	151	151
Other long-term assets	114	117
Total assets	53,951	61,530
Current liabilities:
Accounts payable	3,919	3,501
Accrued expenses	5,208	4,137
Research and development contract liability, current portion	1,790	2,112
Operating lease liabilities, current	3,210
Current portion of long-term debt, net	3,963	3,963
Total current liabilities	18,090	17,081
Operating lease liabilities, non-current	2,579
Long-term debt, net	3,244	4,202
Total liabilities	23,913	24,445
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized; 48,643,316 and 47,215,116 shares issued and outstanding, at March 31, 2024 and December 31, 2023, respectively	48	47
Additional paid in capital	343,527	338,228
Accumulated deficit	(313,537)	(301,190)
Total stockholders' equity	30,038	37,085
Total liabilities and stockholders' equity	$ 53,951	$ 61,530

About Cue Biopharma Inc

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate with Immuno-STAT targeting the KRAS G12V mutation, as well as cancer antigen MAGE-A4; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; and LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

CEO	Mr. Daniel R. Passeri J.D., M.Sc., MSc.
WEBSITE	cuebiopharma.com
INDUSTRY	Biotechnology
EMPLOYEES	51

Cue Biopharma Inc Frequently Asked Questions

What is the ticker symbol for Cue Biopharma Inc? What does CUE stand for in stocks?

CUE is the stock ticker symbol of Cue Biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cue Biopharma Inc (CUE)?

As of Fri May 17 2024, market cap of Cue Biopharma Inc is 83.67 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CUE stock?

You can check CUE's fair value in chart for subscribers.

What is the fair value of CUE stock?

You can check CUE's fair value in chart for subscribers. The fair value of Cue Biopharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cue Biopharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CUE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cue Biopharma Inc a good stock to buy?

The fair value guage provides a quick view whether CUE is over valued or under valued. Whether Cue Biopharma Inc is cheap or expensive depends on the assumptions which impact Cue Biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CUE.

What is Cue Biopharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CUE's PE ratio (Price to Earnings) is -1.67 and Price to Sales (PS) ratio is 11.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CUE PE ratio will change depending on the future growth rate expectations of investors.